LONDON and CAMBRIDGE, Mass., Sept. 19, 2024 /PRNewswire/ -- Beacon Therapeutics Holdings Limited ('Beacon' or 'the Company'), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today presented 36-month...
Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP
Seaking AlphaSeeking Alpha / Seaking Alpha 22 hours ago 1 Views
Comments